Last reviewed · How we verify
Matching placebo to pioglitazone
Matching placebo to pioglitazone is a Thiazolidinedione Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Type 2 diabetes mellitus (placebo control in phase 3 trial).
This is a placebo control arm matching pioglitazone, a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.
This is a placebo control arm matching pioglitazone, a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity. Used for Type 2 diabetes mellitus (placebo control in phase 3 trial).
At a glance
| Generic name | Matching placebo to pioglitazone |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Thiazolidinedione |
| Target | PPAR-γ (Peroxisome proliferator-activated receptor gamma) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Pioglitazone works by binding to and activating PPAR-γ, a nuclear receptor involved in glucose and lipid metabolism. This activation increases insulin sensitivity in muscle and adipose tissue, reducing hepatic glucose production and improving glycemic control in type 2 diabetes. The matching placebo is an inert formulation designed to be indistinguishable from active pioglitazone for blinded trial purposes.
Approved indications
- Type 2 diabetes mellitus (placebo control in phase 3 trial)
Common side effects
- Weight gain
- Fluid retention / edema
- Hypoglycemia
- Heart failure exacerbation
Key clinical trials
- Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration? (PHASE4)
- Bioenergetic Effect of Pioglitazone in CLD-PH (PHASE2)
- The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans (PHASE4)
- Acetazolamide Add-On Therapy to OSA Surgery (PHASE4)
- Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA) (PHASE1)
- Polycystic Ovary Syndrome (PCOS) and Sleep Apnea (PHASE4)
- Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases (PHASE4)
- Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo to pioglitazone CI brief — competitive landscape report
- Matching placebo to pioglitazone updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Matching placebo to pioglitazone
What is Matching placebo to pioglitazone?
How does Matching placebo to pioglitazone work?
What is Matching placebo to pioglitazone used for?
Who makes Matching placebo to pioglitazone?
What drug class is Matching placebo to pioglitazone in?
What development phase is Matching placebo to pioglitazone in?
What are the side effects of Matching placebo to pioglitazone?
What does Matching placebo to pioglitazone target?
Related
- Drug class: All Thiazolidinedione drugs
- Target: All drugs targeting PPAR-γ (Peroxisome proliferator-activated receptor gamma)
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus (placebo control in phase 3 trial)
- Compare: Matching placebo to pioglitazone vs similar drugs
- Pricing: Matching placebo to pioglitazone cost, discount & access